According to the present disclosure, there is provided a method for producing oligodendrocytes and progenitor cells thereof, comprising introducing inducers including a combination of OLIG and SOX or a combination of OLIG and NKX into iPS or ES cells. According to the present disclosure, there is also provided a method for producing oligodendrocytes and progenitor cells thereof, comprising introducing inducers including OLIG, SOX, ASCL, and NKX into somatic cells.
According to the present disclosure, provided is a method for producing stem cells, the method comprising applying tetrakis-pivaloyloxymethyl 2-(thiazol-2-ylamino)ethylidene-1,1-bisphosphonate (PTA) to blood cells or immunocytes, and deriving stem cells from the blood cells or immunocytes.
A valve including a case 3, a tube 1 disposed in the case 3, a hinge fulcrum 4 disposed in the case 3, a contact member 5 connected to the hinge fulcrum 4 and capable of coming into contact with the tube 1, and a driving device 10 configured to apply a non-contact force to the contact member 5 from outside of the case 3 and change a contact force that is applied to the tube 1 by the contact member 5 to change an inner diameter of the tube 1.
The present invention provides a culturing system and method for culturing cells that can culture cells in parallel. The culturing system comprises a cell storage 10 configured to store cells, a plurality of culture apparatuses 20, and a distribution flow path 30 configured to distribute the cells from the cell storage 10 to the culture apparatuses 20, in which each of the culture apparatuses 20 comprises a plurality of culture vessels 21, a supply flow path 22 configured to selectively supply a fluid from the distribution flow path 30 to the culture vessels 21, and a connection flow path 23 configured to connect the culture vessels 21; the culture vessels 21 are connected in series with the connection flow path 23 in each of the culture apparatuses 20; and the supply flow path 22 is configured to selectively supply the fluid to the culture vessels so that the cells are sequentially transferred among the culture vessels 21 through the connection flow path 23 in each of the culture apparatuses 20.
This method for providing a cosmetic or a drug includes obtaining a supernatant of a culture medium of pluripotent stem cells derived from cells that were provided from a subject, and providing, to the subject, a cosmetic or a drug that includes the supernatant of the culture medium. This cosmetic or drug includes a supernatant of a culture medium of pluripotent stem cells derived from cells that were provided from a subject, and is for being provided to the subject.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A method for producing nerve cells includes introducing NGN1 as a differentiation factor into stem cells. A method for producing nerve cells includes introducing only NeuroD4 as a differentiation factor into stem cells. A method for producing motor neurons includes introducing NGN2, ISL2, and LHX4 as differentiation factors into stem cells. A method for producing motor neurons includes introducing NGN1, ISL2, and LHX4 as differentiation factors into stem cells. A method for producing motor neurons includes introducing NeuroD4, ISL2, and LHX4 as differentiation factors into stem cells. A method for screening neurological disease therapeutic drugs includes introducing a differentiation factor into pluripotent stem cells derived from neurological disease patients and differentiating the cells into neural cells, applying a candidate drug to cells during differentiation of the pluripotent stem cells into the neural cells or to the differentiated neural cells, and screening the candidate drug on the basis of on the neural cells.
According to the present disclosure, there is provided a method for producing stem cells including: preparing somatic cells; preparing a chimeric virus including a virus-derived genomic RNA harboring an inducer RNA that induces somatic cells into stem cells and a virus-derived envelope surrounding the genomic RNA, wherein the genomic RNA and the envelope are derived from different viruses; and introducing the inducer RNA into the somatic cells using the chimeric virus.
40 - Treatment of materials; recycling, air and water treatment,
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Manufacturing and culturing of stem cells for others as an ingredient for cosmetics Culture of cells for transplantation taken from the patients themselves
The present disclosure provides a method for producing stem cells, said method comprising applying a phosphate to blood cells and inducing stem cells from the blood cells. The phosphate may be an intermediate or final product of the non-mevalonic acid pathway. The phosphate may be (E)-4-hydroxy-3-methyl-2-butenyl diphosphate.
A pump is provided that includes a tube 1, tube rotors 21A, 21B, and 21C in contact with the tube 1, a case 3 containing the tube 1 and tube rotors 21A, 21B, and 21C, and a drive apparatus 10 that rotates the tube rotors 21A, 21B, and 21C from outside the case 3 without contacting the tube rotors 21A, 21B, and 21C.
According to the present disclosure, there is provided a method for culturing factor-introduced cells, the method including culturing factor-introduced cells and recovering the factor-introduced cells and seeding at least part of the recovered cells in a medium for seeding. In addition, there is provided a method for culturing factor-introduced cells, the method including culturing factor-introduced cells and inducing the factor-introduced cells to somatic cells different from pluripotent stem cells without passaging.
An solution transfer device comprises a pump 60 and a substrate 70. The pump 60 comprises a tube 1 for transferring a solution; tube rotors 21A, 21B, 21C, which contact the tube 1; and a driver 10 for transferring a solution within the tube 1 by rotating the tube rotors 21A, 21B, 21C without contacting the tube rotors 21A, 21B, 21C. The substrate 70 is provided with a solution-transferring flow path that is connected to the tube 1 of the pump 60.
F04C 5/00 - Rotary-piston machines or pumps with the working-chamber walls at least partly resiliently deformable
F04B 43/00 - Machines, pumps, or pumping installations having flexible working members
C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
13.
METHOD FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS
According to the present disclosure, provided is a method for manufacturing induced pluripotent stem cells including preparing cells and introducing RNA into the cells, wherein the RNA includes RNA encoding a reprogramming factor and wherein, in the RNA introduced into the cells, double-stranded RNA is substantially removed.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
14.
METHOD FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS
According to the present disclosure, there is provided a method for manufacturing pluripotent stem cells including introducing a reprogramming factor into cells and seeding the cells, into which the reprogramming factor is introduced, at a low concentration and culturing the cells.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
This cell production device comprises: a cell production plate that includes a fluid circuit in which a plurality of functional sites are integrated; and a closed type connector that connects the fluid circuit to an external space in a closed manner, wherein the fluid circuit comprises, as the plurality of functional sites, an injection and discharge unit that injects or discharges a fluid into or out of the fluid circuit via the closed type connector, a variable volume unit that stores a fluid that is extruded or withdrawn by the injected or discharged fluid, and a cell induction and culture unit that performs at least one of induction and culture of cells based on the injected fluid.
This cell production device comprises: a cell production plate that includes a fluid circuit having a plurality of functional parts integrated therein; and a plurality of closed type connectors that connect the fluid circuit to an external space in a closed manner. The fluid circuit comprises, as the plurality of functional parts: a plurality of injection and discharge units capable of injecting or discharging a plurality of types of fluids into or out of the fluid circuit via the plurality of closed type connectors; a plurality of fluid reservoir units capable of storing the plurality of types of fluids to be injected or discharged; and a cell induction and culture unit that performs at least one of induction and culture of cells based on the stored plurality of types of fluids.
This cell treatment device is provided with: a factor introduction device 30 for introducing a pluripotent induction factor into cells so as to prepare induction factor-introduced cells; and a reprogramming suspension culture vessel for culturing the induction factor-introduced cells that have been prepared by the factor introduction device 30.
A microscope observation system comprises a cell production device provided with a culture vessel in which cells or cell masses are cultured, a microscope device capable of observing an object including cells or cell masses, a conveying apparatus that conveys the microscope device to the cell production device, and an operating control section that sends a command to the conveying apparatus to temporarily move the conveying apparatus from a current position to a relay position and then to move the conveying apparatus to a target position when focusing the microscope device onto the object, wherein a first distance from the current position to the relay position is a distance necessary to drive an actuator by at least a predetermined amount in order to actuate a rotation shaft or a translation shaft of the conveying apparatus, and a second distance from the current position to the target position is a shorter distance than the first distance.
A somatic cell production system comprising a preintroduction cell solution-feeding channel 20 through which a preintroduction cell-containing solution passes, a factor introducing device 30 that is connected to the preintroduction cell solution-feeding channel 20 and introduces a somatic cell inducing factor into preintroduction cells to prepare inducing factor-introduced cells, and a cell preparation device 40 in which the inducing factor-introduced cells are cultured to prepare somatic cells.
A cell culture device (200) includes a cell culture vessel (22) for culturing cells, a factor container (81) for storing a factor, a reagent container (82) for storing a reagent for introducing the factor into the cells, and a flow path for transporting the factor and the reagent from the factor container (81) and the reagent container (82) to the cell culture vessel (22).
A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
This cell production device comprises: a cell production plate with a first side and a second side, comprising a cell induction and culture tank configured to perform at least one of induction and culture of cells, and a culture medium reservoir tank configured to store a culture medium to be supplied to the cell induction and culture tank; a warming element that is arranged at or near the first side of the cell production plate and that warms the cell induction and culture tank; and a cooling element that is arranged at or near the second side of the cell production plate and that cools the culture medium reservoir tank.
A cell processing system comprising an enclosure 601, an outer enclosure 701 that envelops the enclosure 601, an intake air purification filter 602 provided in the enclosure 601, that purifies gas that has been drawn in from outside the enclosure 601, a circulating apparatus, inside the outer enclosure 701, that circulates gas inside and outside the enclosure 601 in such a manner that gas in the outer enclosure 701 is drawn into the enclosure 601 through the intake air purification filter 602 and gas inside the enclosure 601 is discharged into the outer enclosure 701, and a cell processing apparatus for processing of cells, disposed inside the enclosure 601.
The present invention provides a cell culture vessel comprising a container and a container channel that is connected to the container and that is for feeding a fluid into the container, at least a part of the container being gas-permeable.
Provided is a cell culture method including introducing a factor into cells in a cell culture vessel, and culturing the cells into which the factor has been introduced in the same cell culture vessel. Also provided is a mononuclear cell collection method including treating blood to prepare a treated blood from which erythrocytes have been at least partially removed, diluting the treated blood, causing sedimentation of mononuclear cells contained in the diluted treated blood, removing the supernatant from the diluted treated blood, and collecting the mononuclear cells.
Provided is an erythrocyte removal device 100 including a blood container 10 that holds blood and an erythrocyte removal vessel 11 that at least partially removes erythrocytes from blood.
There is provided a cell culture vessel for culturing a cell in an interior thereof, wherein a width of a bottom surface is equal to or larger than a height of a side surface, the cell culture vessel comprising a flow path configured to supply a fluid into the interior, and wherein the interior is able to be closed.
According to the present disclosure, provided is a method for producing oligodendrocytes and progenitor cells thereof, the method including introducing, into iPS cells or ES cells, an inducer that includes a combination of OLIG and SOX or a combination of OLIG and NKX. In addition, according to the present disclosure, provided is a method for producing oligodendrocytes and progenitor cells thereof, the method including introducing, into somatic cells, an inducer that includes OLIG, SOX, ASCL, and NKX.
According to the present disclosure, there is provided a method for culturing cells into which a reprogramming factor is introduced including culturing cells into which a reprogramming factor is introduced; and recovering all cells into which the reprogramming factor is introduced and seeding and passaging at least part of the recovered cells in a medium. In addition, there is provided a method for culturing cells into which a reprogramming factor is introduced, including culturing cells into which a reprogramming factor is introduced; and inducing somatic cells different from pluripotent stem cells without passaging the cells into which the reprogramming factor is introduced.
A cell culture vessel comprising a housing in which a culture chamber is provided. In the housing, at least two holes that connect the outside of the housing and a culture chamber are provided.
This cell production system is provided with: a robot that assists cell production; and a plurality of closed system cell production devices which are affected by the robot in a one-to-many manner, wherein the closed system cell production devices are each provided with a double-sided structure of a dangerous region side affected by the robot and a safe region side on the reverse side of the dangerous region side.
A method for producing a cardiomyocyte including preparing a stem cell, introducing a Sendai virus into the stem cell by infection, expressing mRNA for synthesizing an inducing factor from the Sendai viruses in the stem cell to induce a cardiomyocyte from the stem cell.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
39 - Transport, packaging, storage and travel services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cell culture media, other than for medical or veterinary
purposes; microorganism culture media, other than for
medical or veterinary purposes; biological preparation for
use in cell cultures other than for medical or veterinary
use; chemicals used as ingredients for cosmetics; chemicals
for industrial purposes; culture fluid for human stem cell
as an ingredient for cosmetics manufacturing; stem cells for
research and scientific purposes; cell culture media for
scientific or research purposes. Cosmetics containing culture fluid for human stem cell;
cosmetics; soaps and detergents; dentifrices; perfumery. Stem cells for medical purposes; stem cells for clinical
purposes; stem cells for veterinary purposes; diagnostic
media for bacteriological cultures; cell culture media for
microorganism culture for medical use; cell culture for
medical use; pharmaceutical preparations for human use;
dietary supplements; dietetic preparations adapted for
medical purposes. Storage of stem cell and cells; warehousing services for
deposited frozen stem cell and cells; consultancy and
information relating to warehousing services for deposited
frozen stem cell and cells; warehousing services. Manufacturing of stem cells and cells for others (terms too
vague in the opinion of the International Bureau – Rule 13
(2) (b) of the Regulations); cell culture services for
others (terms too vague in the opinion of the International
Bureau – Rule 13 (2) (b) of the Regulations); stem cell
culture as an ingredient for cosmetics (terms too vague in
the opinion of the International Bureau – Rule 13 (2) (b) of
the Regulations); providing scientific information related
to cell culture; cytogenetic examination; testing,
examination, research and development in the field of
regenerative medicine; testing, examination, research and
development in the field of cytology; cell culture services,
namely, culture of cells for transplant provided from
patients (terms too vague in the opinion of the
International Bureau – Rule 13 (2) (b) of the Regulations);
testing, examination, research and development of cosmetics;
medical laboratory services; research in the field of
pharmaceuticals; providing information about medical and
scientific research in the field of pharmaceuticals;
conducting clinical trials for pharmaceuticals. Stem cell bank services; medical treatment services by using
cultured cells; stem cell therapy services; collection and
preservation of stem cells for use in regenerative medicine;
collection and preservation of human blood; providing
medical information in the field of cells; providing medical
information related to regenerative medicine; provision of
medical information; medical treatment and diagnosis
services by using cultured cells for medical and clinical
purposes; medical services; providing information and data
for medical diagnosis and treatment; medical treatment and
diagnosis by regenerative medicine; medical treatment and
diagnosis services by cell therapy; medical treatment and
consulting services by cell preparations; medical treatment
services not limited to stem cells; preservation of human
blood as a supply source of stem cells; clinical
examination; evaluation of clinical examination; genetic
testing for medical purposes; providing medical facilities;
health clinic services; providing health information;
dietary and nutritional guidance; rental of medical machines
and apparatus.
35.
PLURIPOTENT STEM CELL MANUFACTURING SYSTEM AND METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS
The present invention provides a stem cell manufacturing system comprising: a pre-transfer cell solution sending channel 20 through which a solution containing cells flows; an inducer solution sending mechanism 21 which sends a pluripotency inducer into the pre-transfer cell solution sending channel 20; an inducer transfer apparatus 30 which is connected to the pre-transfer cell solution sending channel 20 and transfers the pluripotency inducer into the cells to produce cells harboring the inducer; a cell cluster production apparatus 40 which cultures the cells harboring the inducer to produce a plurality of cell clusters consisting of stem cells; and a packaging apparatus 100 which sequentially packages the plurality of cell clusters.
This valve is provided with: a case 3; a tube 1 which is disposed in the case 3; a hinge fulcrum 4 which is disposed in the case 3; a contact member 5 which is connected to the hinge fulcrum 4 and which can be brought into contact with the tube 1; and a driving device 10 which applies a contactless force to the contact member 5 from the outside of the case 3 to change a contact force applied to the tube 1 by the contact member 5, thereby changing the inner diameter of the tube 1.
Provided are a pharmaceutical composition or a pharmaceutical composition raw material, which contains supernatant from a culture medium used during culture to induce pluripotent stem cells.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A microscope observation system according to the present invention comprises: a cell production device that comprises a culture tank for culturing cells or a cell mass; a microscope device that can observe a subject including the cells or the cell mass; a conveyance device that conveys the microscope device toward the cell production device; and an operation control unit that, when focusing the microscope device onto the subject, executes an instruction with regard to the conveyance device to temporarily move the conveyance device from the current location thereof to a relay location and then move the conveyance device toward a target location, wherein a first distance from the current location to the relay location is the distance necessary to rotate an actuator for operating at least one rotational axis or translation axis of the conveyance device by at least a prescribed amount, and a second distance from the current location to the target location is shorter than the first distance.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
39 - Transport, packaging, storage and travel services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cell culture media for laboratory use, other than for medical or veterinary purposes; microorganism culture media for laboratory use, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; chemicals used as ingredients for manufacture of cosmetics; chemicals for industrial purposes; culture fluid for human stem cell as an ingredient for cosmetics manufacturing; stem cells for research and scientific purposes; cell culture media for scientific or research purposes Cosmetics containing culture fluid for human stem cell; cosmetics; bath and cosmetic soaps and laundry and dishwasher detergents; dentifrices; perfumery Stem cells for medical purposes; stem cells for clinical medical purposes; stem cells for veterinary purposes; diagnostic media for bacteriological cultures; cell culture media for microorganism culture for medical use; cell culture for medical use; pharmaceutical preparations for human use derived from iPS cells for treating neural disease, muscular disease, heart disease, skin disease, autoimmune disease, kidney disease, eye disease, diabetes, metabolic liver disease, cancers, blood diseases, reproductive organ diseases, lung disease, ear and throat disease, infectious disease, digestive disease and joint disease; pharmaceutical preparations for human use developed by using iPS cells for treating neural disease, muscular disease, heart disease, skin disease, autoimmune disease, kidney disease, eye disease, diabetes, metabolic liver disease, cancers, blood diseases, reproductive organ diseases, lung disease, ear and throat disease, infectious disease, digestive disease and joint disease; dietary supplements; dietetic preparations adapted for medical purposes Storage of stem cell and cells; warehousing services for deposited frozen stem cell and cells; consultancy and information relating to warehousing services for deposited frozen stem cell and cells; warehousing services Cell culture services for scientific and research purposes for others; providing scientific information related to cell culture; cytogenetic examination being cytogenic research services for others; testing examination, research and development in the field of regenerative medicine; testing, examination, research and development in the field of cytology; testing, examination, research and development of cosmetics; medical laboratory services; research in the field of pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; conducting clinical trials for pharmaceuticals Stem cell bank services; medical treatment services by using cultured cells; stem cell therapy services; collection and preservation of stem cells for use in regenerative medicine; collection and preservation of human blood; providing medical information in the field of cells; providing medical information related to regenerative medicine; provision of medical information; medical treatment and diagnosis services by using cultured cells for medical and clinical purposes; medical services; providing information and data for medical diagnosis and treatment; medical treatment and diagnosis by regenerative medicine; medical treatment and diagnosis services by cell therapy; medical treatment and consulting services by cell preparations; medical treatment of speech disorders, breast cancer and infertility, neural disease, muscular disease, heart disease, skin disease, autoimmune disease, kidney disease, eye disease, diabetes, metabolic liver disease, cancers, blood diseases, reproductive organ diseases, lung disease, ear and throat disease, infectious disease, digestive disease and joint disease, not limited to stem cells; preservation of human blood as a supply source of stem cells; clinical medical examination; evaluation of clinical examination for medical purposes; genetic testing for medical purposes; providing medical facilities; Health clinic services; providing health information; dietary and nutritional guidance; rental of medical machines and apparatus
A solution conveyance apparatus comprising: a pump (60) which comprises a tube (1) for circulating a solution, tube rotors (21A), (21B), (21C) which contact the tube (1), and a drive device (10) for rotating the tube rotors (21A), (21B), (21C) without contact with the tube rotors (21A), (21B), (21C) to send the solution in the tube (1); and a substrate (70) provided with a flow channel for circulating the solution, the flow channel being connected to the tube (1) of the pump (60).
C12M 1/00 - Apparatus for enzymology or microbiology
C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
F04C 5/00 - Rotary-piston machines or pumps with the working-chamber walls at least partly resiliently deformable
Provided is a pump provided with: a tube (1); a tube rotor (21A, 21B, 21C) which is in contact with the tube (1); a case (3) for containing the tube (1) and the tube rotor (21A, 21B, 21C); and a drive device (10) for causing the tube rotor (21A, 21B, 21C) to rotate without contacting with the tube rotor (21A, 21B, 21C) from outside of the case (3).
The present disclosure provides a method for culturing factor-introduced cells, said method comprising culturing factor-introduced cells, collecting the factor-introduced cells, and then seeding at least a part of the collected cells in a medium. Also provided is a method for culturing factor-introduced cells, said method comprising culturing factor-introduced cells, and not subculturing the factor-introduced cells but inducing the same into somatic cells that are different from pluripotent stem cells.
The present disclosure provides a method for producing induced pluripotent stem cells, which comprises preparing cells and introducing RNA into the cells. The RNA includes RNA that encodes a reprogramming factor. From the RNA introduced into the cells, double-stranded RNA has substantially been eliminated.
The present disclosure provides a method for producing pluripotent stem cells which includes: introducing a reprogramming factor into cells; and seeding the cells, into which the reprogramming factor has been introduced, at a low concentration and culturing the cells.
A cell culture device 200 equipped with a cell culture vessel 22 for culturing cells, a factor container 81 for housing factors, a reagent container 82 for housing reagents for introducing factors into cells, and a flow path for sending factors and reagents from the factor container 81 and the reagent container 82 to the cell culture vessel 22.
This cell production device comprises: a cell preparation plate that comprises a fluid circuit having a plurality of functional parts integrated therein; and a plurality of closed connectors that connect the fluid circuit to an external space in a closed manner. The fluid circuit comprises, as the plurality of functional parts: a plurality of injection and discharge parts through which a plurality of types of fluids can be injected into the fluid circuit or can be discharged to outside of the fluid circuit via the plurality of closed connectors; a plurality of fluid retention parts which can store the plurality of types of fluids which should be injected or discharged; and a cell induction and culture part which, on the basis of the types of stored fluids, can carry out at least one of inducing or culturing cells.
This cell production device comprises: a cell production plate including a fluid circuit in which multiple functional sites are integrated; and an exclusive connector that exclusively connects the fluid circuit to the outside space. The fluid circuit comprises, as the multiple functional sites, the following: an injection/discharge unit that, through the exclusive connector, injects the fluid into the fluid circuit or discharges the fluid out of the fluid circuit; a variable capacity unit that stores the fluid which is pushed out or pulled in by the fluid that is injected or discharged; and a cell induction/culture unit that performs at least one of cell induction and cell culture on the basis of the injected fluid.
This cell production device has a first side and a second side and comprises: a cell manufacturing plate equipped with a cell induction/culture tank for conducting cell induction and/or culture and a medium storage tank for storing medium supplied to the cell induction/culture tank; a heating element for heating the cell induction/culture tank, the heating element being positioned near the first side of the cell manufacturing plate; and a cooling element for cooling the medium storage tank, the cooling element being positioned near the second side of the cell manufacturing plate.
This cell culturing vessel is for culturing cells inside thereof, and is provided with a flow path which is for supplying a fluid to the inside and in which the width of the bottom surface is not less than the height of a lateral surface, wherein the inside of the cell culturing vessel can be enclosed.
Provided is a cell culture method that comprises introducing a factor into cells in a cell culture vessel, and culturing the cells which contain the factor introduced thereinto in the same cell culture vessel as the aforesaid cell culture vessel. Also provided is a method for collecting mononuclear cells, said method comprising: treating blood to give a treated blood from which erythrocytes are at least partially removed; diluting the treated blood; allowing mononuclear cells, which are contained in the treated blood thus diluted, to sediment; removing the supernatant from the diluted treated blood; and then collecting the mononuclear cells.
A red blood cell removal device 100 provided with: a blood container 10 in which blood is stored; and a red blood cell remover 11 which receives blood from the blood container 10 and removes red blood cells at least partially from the blood.
This method for producing cardiac muscle cells comprises: preparing stem cells; and inducing the stem cells into cardiac muscle cells by introducing a Sendai virus into the stem cells through infection and causing the Sendai virus to express mRNA for synthesizing an inducing factor inside the stem cells.
This cell production system is provided with: a robot that assists cell production; and a plurality of closed system cell production devices which are affected by the robot in a one-to-many manner, wherein the closed system cell production devices are each provided with a double-sided structure of a dangerous region side affected by the robot and a safe region side on the reverse side of the dangerous region side.
36 - Financial, insurance and real estate services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical
purposes, namely, for gene editing, gene collection, and
gene production. Refrigerated medical container for storage, transportation
and cooling of medicines and pharmaceuticals, namely, frozen
storage containers for stem cells. Insurance services, namely, underwriting, issuance and
brokerage of stem cell insurance. Custom manufacture and non-custom manufacture of medical
devices to order and/or specification of others (term
considered too vague by the International Bureau - Rule 13
(2) (b) of the Regulations); biomanufacturing for others,
namely, custom manufacturing and non-custom manufacturing of
medical and biological materials (term considered too vague
by the International Bureau - Rule 13 (2) (b) of the
Regulations); custom manufacture and non-custom manufacture
of machinery for generating stem cells to order and/or
specification of others (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
biomanufacturing for others, namely, custom manufacturing
and non-custom manufacturing of clinical grade cells (term
considered too vague by the International Bureau - Rule 13
(2) (b) of the Regulations); stem cell banking in the nature
of stem cell freezing services. Scientific and medical research in the field of stem cell,
gene research, and gene editing; blood analysis services;
medical and scientific research, namely, testing,
inspection, and research of stem cells; biological cloning
services, namely, organ reproduction services; biological
cloning services, namely, dna, rna and protein reproduction
services; testing, inspection, and research of cosmetics;
collection of biological materials, namely, stem cells for
scientific research purposes; medical and scientific
research services, namely, research in the field of stem
cells and gene diagnostics; dna analysis services for
scientific research purposes; drug discovery services;
scientific research services, namely, research in the field
of regenerative medicine; stem cell and gene expression
analysis for scientific research purposes; stem cell and
epigenetic state analysis for scientific research purposes;
proteomic analysis for scientific research purposes; stem
cell and gene collection services for research purposes. Stem cell and gene collection services for medical purposes;
medical analysis services for diagnostic and treatment
purposes provided by medical laboratories in the nature of
stem cell and gene expression analysis; medical analysis
services for diagnostic and treatment purposes provided by
medical laboratories in the nature of stem cell and
epigenetic state analysis; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories in the nature of proteomic analysis;
healthcare; medical assistance; stem cell therapy and stem
cell production services for medical purposes and research
purposes (term considered too vague by the International
Bureau - Rule 13 (2) (b) of the Regulations); stem cell and
gene banking services; cosmetic surgery services; stem cell
therapy services, namely, stem cell and gene transplantation
services; collection of biological materials, namely, stem
cells for medical treatment purposes; medical analysis
services for diagnostic and treatment purposes provided by
medical laboratories in the nature of stem cell and gene
diagnostic services; medical diagnostic and treatment
services in the field of regenerative medical services.
36 - Financial, insurance and real estate services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical
purposes, namely, for gene editing, gene collection, and
gene production. Refrigerated medical container for storage, transportation
and cooling of medicines and pharmaceuticals, namely, frozen
storage containers for stem cells. Insurance services, namely, underwriting, issuance and
brokerage of stem cell insurance. Custom manufacture and non-custom manufacture of medical
devices to order and/or specification of others (terms too
vague in the opinion of the International Bureau – Rule
13(2)(b) of the Regulations); biomanufacturing for others,
namely, custom manufacturing and non-custom manufacturing of
medical and biological materials (terms too vague in the
opinion of the International Bureau – Rule 13(2)(b) of the
Regulations); custom manufacture and non-custom manufacture
of machinery for generating stem cells to order and/or
specification of others (terms too vague in the opinion of
the International Bureau – Rule 13(2)(b) of the
Regulations); biomanufacturing for others, namely, custom
manufacturing and non-custom manufacturing of clinical grade
cells (terms too vague in the opinion of the International
Bureau – Rule 13(2)(b) of the Regulations); stem cell
banking in the nature of stem cell freezing services. Scientific and medical research in the field of stem cell,
gene research, and gene editing; blood analysis services;
medical and scientific research, namely, testing,
inspection, and research of stem cells; biological cloning
services, namely, organ reproduction services; biological
cloning services, namely, DNA, RNA and protein reproduction
services; testing, inspection, and research of cosmetics;
collection of biological materials, namely, stem cells for
scientific research purposes; medical and scientific
research services, namely, research in the field of stem
cells and gene diagnostics; DNA analysis services for
scientific research purposes; drug discovery services;
scientific research services, namely, research in the field
of regenerative medicine; stem cell and gene expression
analysis for scientific research purposes; stem cell and
epigenetic state analysis for scientific research purposes;
proteomic analysis for scientific research purposes. Stem cell and gene collection services for medical purposes
and research purposes; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories in the nature of stem cell and gene expression
analysis; medical analysis services for diagnostic and
treatment purposes provided by medical laboratories in the
nature of stem cell and epigenetic state analysis; medical
analysis services for diagnostic and treatment purposes
provided by medical laboratories in the nature of proteomic
analysis; healthcare; medical assistance; stem cell therapy
and stem cell production services for medical purposes and
research purposes (terms too vague in the opinion of the
International Bureau – Rule 13(2)(b) of the Regulations);
cosmetic surgery services; stem cell therapy services,
namely, stem cell and gene transplantation services;
collection of biological materials, namely, stem cells for
medical treatment purposes; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories in the nature of stem cell and gene diagnostic
services; medical diagnostic and treatment services in the
field of regenerative medical services.
36 - Financial, insurance and real estate services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical
purposes, namely, for gene editing, gene collection, and
gene production. Refrigerated medical container for storage, transportation
and cooling of medicines and pharmaceuticals, namely, frozen
storage containers for stem cells. Insurance services, namely, underwriting, issuance and
brokerage of stem cell insurance. Custom manufacture and non-custom manufacture of medical
devices to order and/or specification of others (terms too
vague in the opinion of the International Bureau – Rule 13
2)(b) of the regulations); custom manufacture and non-custom
manufacture of medical devices to order and/or specification
of others (terms too vague in the opinion of the
International Bureau – Rule 13(2)(b) of the regulations);
custom manufacture and non-custom manufacture of machinery
for generating stem cells to order and/or specification of
others (terms too vague in the opinion of the International
Bureau – Rule 13(2)(b) of the regulations); biomanufacturing
for others, namely, custom manufacturing and non-custom
manufacturing of clinical grade cells (terms too vague in
the opinion of the International Bureau – Rule 13(2)(b) of
the regulations); stem cell banking in the nature of stem
cell freezing services. Scientific and medical research in the field of stem cell,
gene research, and gene editing; blood analysis services;
medical and scientific research, namely, testing,
inspection, and research of stem cells; biological cloning
services, namely, organ reproduction services; biological
cloning services, namely, DNA, RNA and protein reproduction
services; testing, inspection, and research of cosmetics;
collection of biological materials, namely, stem cells for
scientific research purposes; medical and scientific
research services, namely, research in the field of stem
cells and gene diagnostics; DNA analysis services for
scientific research purposes; drug discovery services;
scientific research services, namely, research in the field
of regenerative medicine; stem cell and gene expression
analysis for scientific research purposes; stem cell and
epigenetic state analysis for scientific research purposes;
proteomic analysis for scientific research purposes. Stem cell and gene collection services for medical purposes
and research purposes; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories in the nature of stem cell and gene expression
analysis; medical analysis services for diagnostic and
treatment purposes provided by medical laboratories in the
nature of stem cell and epigenetic state analysis; medical
analysis services for diagnostic and treatment purposes
provided by medical laboratories in the nature of proteomic
analysis; healthcare; medical assistance; stem cell therapy
and stem cell production services for medical purposes and
research purposes (terms too vague in the opinion of the
International Bureau – Rule 13(2)(b) of the regulations);
cosmetic surgery services; stem cell therapy services,
namely, stem cell and gene transplantation services;
collection of biological materials, namely, stem cells for
medical treatment purposes; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories in the nature of stem cell and gene diagnostic
services; medical diagnostic and treatment services in the
field of regenerative medical services.
59.
HEALTH RISK INFORMATION MANAGEMENT DEVICE, HEALTH RISK INFORMATION MANAGEMENT METHOD, AND PROGRAM
The present invention comprises a predicted health risk information acquisition part and a cultured cell production determination part. The predicted health risk information acquisition part acquires information about the predicted health risks of a user. On the basis of the predicted health risk information, the cultured cell production determination part determines whether to produce cultured cells from the cells of the user.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
The present invention comprises a predicted health risk information acquisition part and a cultured cell production determination part. The predicted health risk information acquisition part acquires information about the predicted health risks of a user. On the basis of the predicted health risk information, the cultured cell production determination part determines whether to produce cultured cells from the cells of the user.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
Provided is a pharmaceutical composition including a supernatant of a culture medium that has been used for maintenance culture of stem cells in an undifferentiated state. The stem cells for the pharmaceutical composition may be pluripotent stem cells.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
Provided is a pharmaceutical composition or a pharmaceutical composition raw material which contains a supernatant of a medium in which pluripotent stem cells have been differentiated and cultured.
A cell incubator is provided with: a culture component permeation member 10 in which a culture component is permeable; a culture tank 30 for cultivating cells that covers one surface of the culture component permeation member 10 and that holds a cell-containing medium; and a medium-holding tank 40 that is for holding a medium and that covers the other surface of the culture component permeation member 10.
A system for an iPS cell bank includes a terminal and a server. The terminal receives and sends a production request including a desired collection date of a somatic cell and a customer ID to the server. The server stores a collectable date for collecting the somatic cell, a producible period for producing an iPS cell, and a location and a stockable period for stocking the iPS cell; and determines: a collection date based on the desired collection date and the collectable date; a production period based on the collection date and the producible period; an acceptance date of the somatic cell based on the collection date and the production period; a stock location and a stock period based on the production period, the stockable location, and the stockable period; and a shipment date of the iPS cell based on the production period, the stockable location, and the stockable period.
A stem cell manufacturing system for manufacturing stem cells from somatic cells includes: one or more closed production device(s) configured to produce stem cells from somatic cells; one or more drive device(s) configured to be connected with the production device(s) and drive the production device(s) in such a manner as to maintain the production device(s) in an environment suitable for producing stem cells; one or more cryopreservation device(s) configured to cryopreserve the produced stem cells; a first memory device configured to store whether or not somatic cells have been introduced to the production device(s), as a first state; a second memory device configured to store whether or not the production device(s) is/are connected with the drive device(s), as a second state; and a third memory device configured to store whether or not the produced stem cells can be placed in the cryopreservation device(s), as a third state.
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12M 1/02 - Apparatus for enzymology or microbiology with heat exchange means
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
C12M 1/00 - Apparatus for enzymology or microbiology
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
68.
Stem cell manufacturing system, stem cell information management system, cell transport apparatus, and stem cell frozen storage apparatus
A stem cell manufacturing system for manufacturing stem cells from somatic cells includes: one or more closed production device(s) configured to produce stem cells from somatic cells; one or more drive device(s) configured to be connected with the production device(s) and drive the production device(s) in such a manner as to maintain the production device(s) in an environment suitable for producing stem cells; one or more cryopreservation device(s) configured to cryopreserve the produced stem cells; a first memory device configured to store whether or not somatic cells have been introduced to the production device(s), as a first state; a second memory device configured to store whether or not the production device(s) is/are connected with the drive device(s), as a second state; and a third memory device configured to store whether or not the produced stem cells can be placed in the cryopreservation device(s), as a third state.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
C12M 1/00 - Apparatus for enzymology or microbiology
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
A stem cell manufacturing system for manufacturing stem cells from somatic cells includes: one or more closed production device(s) configured to produce stem cells from somatic cells; one or more drive device(s) configured to be connected with the production device(s) and drive the production device(s) in such a manner as to maintain the production device(s) in an environment suitable for producing stem cells; one or more cryopreservation device(s) configured to cryopreserve the produced stem cells; a first memory device configured to store whether or not somatic cells have been introduced to the production device(s), as a first state; a second memory device configured to store whether or not the production device(s) is/are connected with the drive device(s), as a second state; and a third memory device configured to store whether or not the produced stem cells can be placed in the cryopreservation device(s), as a third state.
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12M 1/02 - Apparatus for enzymology or microbiology with heat exchange means
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
A first terminal determines a collection date of a somatic cell based on a desired collection date and a collectable date transmitted by a second medium; and outputs the collection date to a first medium. A second terminal outputs the collectable date to the second medium; and determines an acceptance date based on the collection date transmitted by the first medium and a production period of an iPS cell transmitted by a third medium. A third terminal determines the production period based on the collection date and a producible period, and determines a shipment date based on the production period and stockable location and period transmitted by a fourth medium; and outputs the production period to the third medium. A fourth terminal outputs the stockable location and period to the fourth medium; and determines stock location and period based on the production period and the stockable location and period.
G06Q 10/06 - Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical purposes, namely, for gene editing, gene collection, and gene production Refrigerated medical container for storage, transportation and cooling of medicines and pharmaceuticals, namely, frozen storage containers for stem cells Manufacture of medical devices to order and/or specification of others; biomanufacturing for others, namely, manufacturing of medical and biological materials; manufacture of machinery for generating stem cells to order and/or specification of others; biomanufacturing for others, namely, manufacturing of clinical grade cells Scientific and medical research in the field of stem cell, gene research, and gene editing; blood analysis services; medical and scientific research, namely, testing, inspection, and research of stem cells; biological cloning services, namely, organ reproduction services; biological cloning services, namely, DNA, RNA and protein reproduction services; testing, inspection, and research of cosmetics; Collection of biological materials, namely, stem cells for scientific research purposes; medical and scientific research services, namely, research in the field of stem cells and gene diagnostics; DNA analysis services for scientific research purposes; drug discovery services; scientific research services, namely, research in the field of regenerative medicine; stem cell and gene expression analysis for scientific research purposes; stem cell and epigenetic state analysis for scientific research purposes; proteomic analysis for scientific research purposes Stem cell and gene collection services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene expression analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and epigenetic state analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of proteomic analysis; healthcare; medical assistance; stem cell therapy and stem cell production services; stem cell and gene banking services; stem cell banking in the nature of stem cell freezing services; cosmetic surgery services; stem cell therapy services, namely, stem cell and gene transplantation services; collection of biological materials, namely, stem cells for medical treatment purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene diagnostic services; medical diagnostic and treatment services in the field of regenerative medical services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical purposes, namely, for gene editing, gene collection, and gene production Refrigerated medical container for storage, transportation and cooling of medicines and pharmaceuticals, namely, frozen storage containers for stem cells Manufacture of medical devices to order and/or specification of others; biomanufacturing for others, namely, manufacturing of medical and biological materials; manufacture of machinery for generating stem cells to order and/or specification of others; biomanufacturing for others, namely, manufacturing of clinical grade cells Scientific and medical research in the field of stem cell, gene research, and gene editing; blood analysis services; medical and scientific research, namely, testing, inspection, and research of stem cells; biological cloning services, namely, organ reproduction services; biological cloning services, namely, DNA, RNA and protein reproduction services; testing, inspection, and research of cosmetics; Collection of biological materials, namely, stem cells for scientific research purposes; medical and scientific research services, namely, research in the field of stem cells and gene diagnostics; DNA analysis services for scientific research purposes; drug discovery services; scientific research services, namely, research in the field of regenerative medicine; stem cell and gene expression analysis for scientific research purposes; stem cell and epigenetic state analysis for scientific research purposes; proteomic analysis for scientific research purposes Stem cell and gene collection services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene expression analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and epigenetic state analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of proteomic analysis; healthcare; medical assistance; stem cell therapy and stem cell production services; stem cell and gene banking services; stem cell banking in the nature of stem cell freezing services; cosmetic surgery services; stem cell therapy services, namely, stem cell and gene transplantation services; collection of biological materials, namely, stem cells for medical treatment purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene diagnostic services; medical diagnostic and treatment services in the field of regenerative medical services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Apparatus for the regeneration of stem cells for medical purposes, namely, for gene editing, gene collection, and gene production Refrigerated medical container for storage, transportation and cooling of medicines and pharmaceuticals, namely, frozen storage containers for stem cells Manufacture of medical devices to order and/or specification of others; biomanufacturing for others, namely, manufacturing of medical and biological materials; manufacture of machinery for generating stem cells to order and/or specification of others; biomanufacturing for others, namely, manufacturing of clinical grade cells Scientific and medical research in the field of stem cell, gene research, and gene editing; blood analysis services; medical and scientific research, namely, testing, inspection, and research of stem cells; biological cloning services, namely, organ reproduction services; biological cloning services, namely, DNA, RNA and protein reproduction services; testing, inspection, and research of cosmetics; Collection of biological materials, namely, stem cells for scientific research purposes; medical and scientific research services, namely, research in the field of stem cells and gene diagnostics; DNA analysis services for scientific research purposes; drug discovery services; scientific research services, namely, research in the field of regenerative medicine; stem cell and gene expression analysis for scientific research purposes; stem cell and epigenetic state analysis for scientific research purposes; proteomic analysis for scientific research purposes Stem cell and gene collection services; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene expression analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and epigenetic state analysis; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of proteomic analysis; healthcare; medical assistance; stem cell therapy and stem cell production services; stem cell and gene banking services; stem cell banking in the nature of stem cell freezing services; cosmetic surgery services; stem cell therapy services, namely, stem cell and gene transplantation services; collection of biological materials, namely, stem cells for medical treatment purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories in the nature of stem cell and gene diagnostic services; medical diagnostic and treatment services in the field of regenerative medical services
Provided is a method for producing neural cells, the method including: preparing stems cells; and introducing Sendai virus into the stem cells via infection, and causing the Sendai virus to express induction-factor-synthesizing mRNA within the stem cells to induce the stem cells into neural cells.
Provided is a pharmaceutical composition including a supernatant of a culture medium that has been used for maintenance culture of stem cells in an undifferentiated state. The stem cells for the pharmaceutical composition may be pluripotent stem cells.
The present invention provides a stem cell manufacturing system comprising: a sending channel (20) through which a solution containing cells flows; an apparatus (30) which is connected to the sending channel (20) and transfers a pluripotency inducer into the cells to produce cells harboring the inducer; and an apparatus (40) which cultures the cells harboring the inducer to produce cell clusters consisting of stem cells.
This somatic cell production system is provided with: a pre-introduction cell liquid supply channel 20 through which a solution containing pre-introduction cells is passed; a factor introduction device 30 which is connected to the pre-introduction cell liquid supply channel 20 and which introduces a somatic cell inducing factor into the pre-introduction cells so as to prepare inducing factor-introduced cells; and a cell preparation device 40 for culturing the inducing factor-introduced cells to prepare somatic cells.
The present disclosure provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, and introducing a Sendai virus including reprogramming factor RNA into the somatic cell. The present disclosure also provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, introducing reprogramming factor RNA into the somatic cells using an RNA transfection reagent, and reprogramming the somatic cells in a gel culture medium.
This insurance management system is provided with an insurance management server, wherein the insurance management server has a reception unit that receives a prescribed amount of money deposited by a user for a prescribed period, a production request transmission unit that transmits a customer's specific cell production request to a cell management server for managing production of specific cells, when the accumulated amount of money deposited by the user and received by the reception unit satisfies a first condition; and a use request transmission unit that transmits a customer's specific cell use request to the cell management server when the accumulated amount of money received by the reception unit satisfies a second condition larger in amount or longer in period than the first condition.
This temperature control case is provided with: an outer case 1; a thermal insulation material 2 disposed inside the outer case 1; and a heat storage material 3 which is disposed inside the thermal insulation material 2 and has a container 4 disposed therein.
B65D 81/18 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
81.
PRODUCTION METHOD FOR ARTIFICIAL PLURIPOTENT STEM CELLS
The present disclosure provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, and introducing a Sendai virus including reprogramming factor RNA into the somatic cell. The present disclosure also provides a production method for artificial pluripotent stem cells, the method comprising preparing somatic cells, introducing reprogramming factor RNA into the somatic cells using an RNA transfection reagent, and reprogramming the somatic cells in a gel culture medium.
The present invention provides a nerve cell production method that involves preparing stem cells and then introducing inducing-factor RNA into the stem cells and allowing differentiation into nerve cells. The present invention also provides a nerve cell production method that involves preparing cells, introducing reprogramming-factor RNA into the cells, introducing inducing-factor RNA into the cells into which the reprogramming-factor RNA was introduced, and allowing differentiation into nerve cells.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
This cell treatment device is provided with: a factor introduction device 30 for introducing a pluripotent induction factor into cells so as to prepare induction factor-introduced cells; and a reprogramming suspension culture vessel for culturing the induction factor-introduced cells that have been prepared by the factor introduction device 30.
The present invention provides a nerve cell production method that involves preparing stem cells and then introducing inducing-factor RNA into the stem cells and allowing differentiation into nerve cells. The present invention also provides a nerve cell production method that involves preparing cells, introducing reprogramming-factor RNA into the cells, introducing inducing-factor RNA into the cells into which the reprogramming-factor RNA was introduced, and allowing differentiation into nerve cells.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
85.
CELL PROCESSING SYSTEM AND CELL PROCESSING APPARATUS
This cell processing system is provided with a housing 601, an outer housing 701 which contains the housing 601, an intake air purification filter 602 which is provided in the housing 601, and purifies a gas suctioned from the exterior of the housing 601, a circulation device which circulates a gas in and out of the housing 601, in the outer housing 701, so that the gas in the outer housing 701 is suctioned into the housing 601 through the intake air purification filter 602, and the gas in the housing 601 is discharged into the outer housing 701, and a cell processing device which is disposed in the housing 601, and which is for processing cells.
A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
This somatic cell production system is provided with: a pre-introduction cell liquid supply channel 20 through which a solution containing pre-introduction cells is passed; a factor introduction device 30 which is connected to the pre-introduction cell liquid supply channel 20 and which introduces a somatic cell inducing factor into the pre-introduction cells so as to prepare inducing factor-introduced cells; and a cell preparation device 40 for culturing the inducing factor-introduced cells to prepare somatic cells.
This cell processing system is provided with a housing 601, an outer housing 701 which contains the housing 601, an intake air purification filter 602 which is provided in the housing 601, and purifies a gas suctioned from the exterior of the housing 601, a circulation device which circulates a gas in and out of the housing 601, in the outer housing 701, so that the gas in the outer housing 701 is suctioned into the housing 601 through the intake air purification filter 602, and the gas in the housing 601 is discharged into the outer housing 701, and a cell processing device which is disposed in the housing 601, and which is for processing cells.
This cell treatment device is provided with: a factor introduction device 30 for introducing a pluripotent induction factor into cells so as to prepare induction factor-introduced cells; and a reprogramming suspension culture vessel for culturing the induction factor-introduced cells that have been prepared by the factor introduction device 30.
This insurance management system is provided with an insurance management server, wherein the insurance management server has a reception unit that receives a prescribed amount of money deposited by a user for a prescribed period, a production request transmission unit that transmits a customer's specific cell production request to a cell management server for managing production of specific cells, when the accumulated amount of money deposited by the user and received by the reception unit satisfies a first condition; and a use request transmission unit that transmits a customer's specific cell use request to the cell management server when the accumulated amount of money received by the reception unit satisfies a second condition larger in amount or longer in period than the first condition.
A system for an iPS cell bank includes a terminal and a server. The terminal receives and sends a production request including a desired collection date of a somatic cell and a customer ID to the server. The server stores a collectable date for collecting the somatic cell, a producible period for producing an iPS cell, and a location and a stockable period for stocking the iPS cell; and determines: a collection date based on the desired collection date and the collectable date; a production period based on the collection date and the producible period; an acceptance date of the somatic cell based on the collection date and the production period; a stock location and a stock period based on the production period, the stockable location, and the stockable period; and a shipment date of the iPS cell based on the production period, the stockable location, and the stockable period.
A first terminal determines a collection date of a somatic cell based on a desired collection date and a collectable date transmitted by a second medium; and outputs the collection date to a first medium. A second terminal outputs the collectable date to the second medium; and determines an acceptance date based on the collection date transmitted by the first medium and a production period of an iPS cell transmitted by a third medium. A third terminal determines the production period based on the collection date and a producible period, and determines a shipment date based on the production period and stockable location and period transmitted by a fourth medium; and outputs the production period to the third medium. A fourth terminal outputs the stockable location and period to the fourth medium; and determines stock location and period based on the production period and the stockable location and period.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
93.
Stem cell manufacturing system, stem cell information management system, cell transport apparatus, and stem cell frozen storage apparatus
A stem cell manufacturing system for manufacturing stem cells from somatic cells includes: one or more closed production device(s) configured to produce stem cells from somatic cells; one or more drive device(s) configured to be connected with the production device(s) and drive the production device(s) in such a manner as to maintain the production device(s) in an environment suitable for producing stem cells; one or more cryopreservation device(s) configured to cryopreserve the produced stem cells; a first memory device configured to store whether or not somatic cells have been introduced to the production device(s), as a first state; a second memory device configured to store whether or not the production device(s) is/are connected with the drive device(s), as a second state; and a third memory device configured to store whether or not the produced stem cells can be placed in the cryopreservation device(s), as a third state.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
94.
METHOD FOR PREPARING POPULATION OF STEM CELL SPHEROIDS
The invention is a spheroid formation method. In the method, two or more cell clusters (42a)-(42c) are distributed to each of two or more compartments (32a), (32b). Two or more cell clusters (42a), (42b) are brought close to each other in each compartment (32a), (32b). The two or more cell clusters (42a), (42b) that are brought close to each other are aggregated. Spheroids are formed by growing the aggregated cell clusters. The distributed cell clusters (42a)-(42c) are separated from each other and mixed with each other. The cell clusters (42a)-(42c) are each constituted by stem cells.
A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
The present invention provides a stem cell manufacturing system comprising: a sending channel (20) through which a solution containing cells flows; an apparatus (30) which is connected to the sending channel (20) and transfers a pluripotency inducer into the cells to produce cells harboring the inducer; and an apparatus (40) which cultures the cells harboring the inducer to produce cell clusters consisting of stem cells.
The present invention provides a stem cell manufacturing system comprising: a sending channel (20) through which a solution containing cells flows; an apparatus (30) which is connected to the sending channel (20) and transfers a pluripotency inducer into the cells to produce cells harboring the inducer; and an apparatus (40) which cultures the cells harboring the inducer to produce cell clusters consisting of stem cells.
A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
